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Background: Miller-Fisher Syndrome (MFS) is a rare acute polyneuropathy composed of the
clinical triad of ataxia, areﬂexia and ophthalmoplegia, with a monophasic, self-limited
course and spontaneous improvement.
Case report: The authors present a 65-year-old man with Miller-Fisher syndrome consisting
of bilateral ophthalmoplegia, trigeminal and facial nerve palsy, mild ataxia and peripheral
neuropathy. The disease had a progressive, subacute course within 3 months. A high titer of
anti-GQ1b antibodies was detected. As a result of plasmapheresis, complete recovery was
achieved.
Conclusions: The presented case was atypical in its clinical course and treatment. It could
support the theory of the continuity between MFS, Bickerstaff brainstem encephalitis (BBE),
and Guillain–Barré syndrome (GBS).
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Miller-Fisher Syndrome (MFS) is a rare acute polyneuropathy
composed of the clinical triad of ataxia, areﬂexia and
ophtalmoplegia. The presence anti-ganglioside GQ1b (anti-
GQ1b) antibodies in serum is a powerful diagnostic marker of
MFS. This syndrome is typically characterized by acute onset, a
monophasic, and self-limited course with spontaneous im-
provement. Recovery from MFS is good, usually without any
residual deﬁcits [1,2].
The authors present an unusual MFS case with a subacute,
and progressive course, with polycranial nerve palsy. Clinical* Corresponding author at: Department of Neurology, Wrocław Medica
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titer was achieved after plasmapheresis.
2. Case report
A 65-year-old man, without any signiﬁcant medical history,
developed diplopia, left trigeminal nerve palsy, and a mild
headache one month after an upper respiratory infection. Brain
CT and MRI with contrast were within normal limits. Two
months later progressive ocular disturbances with right ptosis,
severe headache in the right frontal area which was not
responsive to analgetics, and an unsteady gait occurred.
Neurological examination revealed hyperaesthesia in the ﬁrstl University, Borowska 213, 50-556 Wrocław, Poland.
rosół).
p. z o.o. All rights reserved.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 1 3 7 – 1 3 8138branch of the right trigeminal nerve, bilateral ophtalmoplegia
with minimal pupil reaction to light, right ptosis, mild ataxia
and diminished tendon reﬂexes, ataxic gait on the wide base.
Three weeks later he developed left peripheral-type facial palsy.
All the time he had a severe headache, burning and itching
of the face, sleep disturbance, anxiety and mild agitation.
The immunological study was positive for anti-GQ1b
antibodies (1:1280, normal value < 1:160). Serologic analysis
of antibodies against other gangliosides (GM1, GD1b), auto-
antibodies (ANCA, ANA, PANCA, CANCA, cardiolipin, anti-
DNA, ENA, b2-glycoprotein), neuro-oncological antibodies,
anti-GAD, anti-MAG, anti-myelin, anti-unmyelinated nerve
ﬁbers, and anti-neuroendothelium were negative. Borrelia
burgdorferi, hepatitis viruses C and B, HIV and VDRL tests were
also negative. In the cerebrospinal ﬂuid a mild protein level
elevation was seen with a normal number of cells.
A nerve conduction study showed a slight, axonal, mainly
sensory neuropathy. Neurographic examination of the left
facial nerve revealed lowering of the amplitude with slight
prolongation of the conduction time (frontal muscle – 0.35 ms/
cm, orbicularis oculi muscle – 0.37 ms/cm, orbicularis oris
muscle – 0.37 ms/cm). EMG from orbicularis oculi muscle
showed neurogenic changes. A repetitive nerve stimulation
test was negative. An EEG showed diffuse slow activity, single
delta waves with a slightly higher amplitude over both temporo-
parietal areas. The latencies of left BAEP's waves III and V, and
inter-peak latencies I–III and I–V were delayed. A brain MRI with
gadolinium revealed enhancement of the left facial nerve with
no brainstem abnormalities.
The patient underwent ﬁve sessions of plasma exchange.
After this treatment the clinical improvement was observed.
Three months later the patient had no neurological deﬁcit, EEG
was normal, and the anti-GQ1b antibody titer was signiﬁcantly
lower (1:320).
3. Discussion
An analysis of MFS cases showed that its occurrence is seasonal,
predominating in spring (March to May), in most cases after
respiratory symptoms (76%), and the median time of improve-
ment is 4–6 days (range 2–21 days) after the neurological onset
[1–3]. In our patient the beginning of the disease was in April, a
month after the upper respiratory infection, but his neurological
symptoms progressed within three months. He had a mild
headache, left oculomotor and trigeminal nerve palsy. Two
months later he developed a severe headache, unstable gait,
bilateral ophthalmoplegia, and one month later left facial nerve
palsy occurred. In MFS patients the median interval between
neurological onset and the beginning of recovery, usually
without immunological treatment, is about 12–15 days [1,2]. In
our patient complete neurological improvement was observed
more than three months after the onset, and exclusively after
the immunological treatment. According to Mori et al. [2],
plasmapheresis has no beneﬁcial effect in MFS patients, it even
worsens facial palsy.
Headache is not a common symptom in MFS. Friedman
and Potts [4] suggested that headache might be caused
by antibody-mediated effects on the trigemino-vascular painpathway. The hyperaesthesia, burning and itching of the face
could indicate trigeminal nerve impairment.
In most MFS cases neuro-images are unremarkable. In
some patients lesions of the brainstem, dorsal root ganglia,
lumbosacral roots and the posterior column of the spinal cord
were seen in MRI. In a few cases trochlear, abducens and
oculomotor nerve enhancement has been found in MR scans
[2,5]. We observed a similar enhancement of the left facial
nerve. Although we did not reveal any brain changes in MRI,
mild behavioral disorders, abnormal EEG and BAEP could
indicate central nervous system involvement in our patient.
Our ﬁndings could support the hypothesis of the continuity
between MFS and BBE. The presence of anti-GQ1b antibody
syndrome is proposed to associate MFS, BBE and GBS, known
as an ‘‘anti-GQ1b antibody syndrome’’ [1–3].
The presented case is atypical because of its subacute and
progressive course, and improvement exclusively after the
immunological treatment. The clinical course, and the result
of diagnostics, could support the theory of the continuity
between MFS, BBE, and GBS.
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